



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: [www.shyuanye.com](http://www.shyuanye.com)  
邮箱: [shyysw@sina.com](mailto:shyysw@sina.com)

产品名称: **TCS-OX2-29**  
产品别名: **TCS-OX2-29**

|                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>生物活性:</b>                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Description</b>                  | TCS-OX2-29 is a potent, high affinities and selective orexin-2 receptor (OX <sub>2</sub> R) antagonist with an IC <sub>50</sub> value of 40 nM and a pK <sub>i</sub> value of 7.5. TCS-OX2-29 displays ~250-fold selectivity for OX <sub>2</sub> over OX <sub>1</sub> [1][2].                                                                                                                                                                                                                                                                                           |
| <b>IC<sub>50</sub> &amp; Target</b> | IC50: 40 nM (OX <sub>2</sub> R)[1]; pKi: 7.5 (OX <sub>2</sub> R)[2]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>In Vitro</b>                     | TCS-OX2-29 inhibits orexin A induced IP3 accumulation and ERK1/2 phosphorylation in CHO cells transfected with the OX <sub>2</sub> receptor[2].                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>In Vivo</b>                      | TCS-OX2-29 (5-10 mg/kg; intraperitoneal injection; adult male NMRI mice) treatment suppresses conditioned place preference (CPP) acquisition and expression in both naïve and dependent mice significantly[3].                                                                                                                                                                                                                                                                                                                                                          |
|                                     | <b>Animal Model:</b> 440 adult male NMRI mice (25-30 g)[3]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|                                     | <b>Dosage:</b> 5 mg/kg and 10 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                     | <b>Administration:</b> Intraperitoneal injection (Pharmacokinetic study)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Solvent&amp;Solubility</b>       | <b>Result:</b> Suppressed conditioned place preference (CPP) acquisition and expression in both naïve and dependent mice significantly.                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|                                     | <b>In Vitro:</b><br>H <sub>2</sub> O : < 0.1 mg/mL (insoluble)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>References</b>                   | [1]. Hirose M et al. N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett, 2003 Dec 15, 13(24):4497-9.<br>[2]. Tabaeizadeh M, et al. The differential effects of OX1R and OX2R selective antagonists on morphine conditioned place preference in naïve versus morphine-dependent mice. Behav Brain Res. 2013 Jan 15;237:41-8.<br>[3]. R Mould et al. Binding kinetics differentiates functional antagonism of orexin-2 receptor ligands. Br J Pharmacol. 2014 Jan; 171(2): 351-363. |